SRDX - SurModics - Biotech IPO Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SRDX - SurModics - Biotech IPO

SRDX 31.15

+5.7%

Apr 28 3:59 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Lance Bredvold	1/6/2024 2:16:22 PM
	of 83

Medtronic (headquartered in Ireland where SRDX does most equip. mfg) was a major customer of ours buying coatings for various stents. I now read a rather casual statement on Value Line indicating that they divested their "slow growth" deep vein thrombosis business though I don't know to whom. I would have expected to know if SRDX had bought it and would have thought that likely because of their relationship and also because SRDX is making a major effort with their POUNCE deep vein tool lineup. I should go to MDT's reports to see what became of that business and to decide whether SRDX is really likely to earn a good return on it's investment there. I think the arterial stents are really the bigger business in their view while tools to extract clots from veins is a nice supplemental business. POUNCE was approved much sooner than Surveil and the other model of arterial stent. It provided something for the new sales force to concentrate on while awaiting further FDA approvals.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next